BR112018005305A2 - agente profilático ou terapêutico da queratite fungal - Google Patents

agente profilático ou terapêutico da queratite fungal

Info

Publication number
BR112018005305A2
BR112018005305A2 BR112018005305-8A BR112018005305A BR112018005305A2 BR 112018005305 A2 BR112018005305 A2 BR 112018005305A2 BR 112018005305 A BR112018005305 A BR 112018005305A BR 112018005305 A2 BR112018005305 A2 BR 112018005305A2
Authority
BR
Brazil
Prior art keywords
mycosis
cornea
prevention
treatment agent
medical treatment
Prior art date
Application number
BR112018005305-8A
Other languages
English (en)
Japanese (ja)
Portuguese (pt)
Inventor
Zhang Jinzhong
Kageyama Masaaki
Original Assignee
Santen Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Santen Pharmaceutical Co., Ltd. filed Critical Santen Pharmaceutical Co., Ltd.
Publication of BR112018005305A2 publication Critical patent/BR112018005305A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
BR112018005305-8A 2015-09-18 2016-09-13 agente profilático ou terapêutico da queratite fungal BR112018005305A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562220847P 2015-09-18 2015-09-18
US62/220,847 2015-09-18
PCT/JP2016/077014 WO2017047597A1 (ja) 2015-09-18 2016-09-13 角膜真菌症の予防または治療剤

Publications (1)

Publication Number Publication Date
BR112018005305A2 true BR112018005305A2 (pt) 2018-10-09

Family

ID=58288799

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018005305-8A BR112018005305A2 (pt) 2015-09-18 2016-09-13 agente profilático ou terapêutico da queratite fungal

Country Status (13)

Country Link
US (1) US10166217B2 (enExample)
EP (1) EP3351244A4 (enExample)
JP (1) JP6639364B2 (enExample)
KR (1) KR20180053340A (enExample)
CN (1) CN108025000A (enExample)
BR (1) BR112018005305A2 (enExample)
HK (2) HK1253545A1 (enExample)
MX (1) MX393608B (enExample)
MY (1) MY183906A (enExample)
PH (1) PH12018500579A1 (enExample)
SG (1) SG11201802091RA (enExample)
TW (1) TWI721015B (enExample)
WO (1) WO2017047597A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112957321B (zh) * 2021-03-04 2022-08-05 青岛大学附属医院 一种氧化硫酸软骨素改性的那他霉素滴眼液及其制备方法
CN114568490B (zh) * 2022-04-01 2023-12-19 眉山职业技术学院(眉山技师学院) 雷帕霉素在抑制柑橘青霉菌生长中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006213673A1 (en) 2005-02-09 2006-08-17 Santen Pharmaceutical Co., Ltd. Formulations for ocular treatment
CN101137369A (zh) * 2005-02-09 2008-03-05 马库赛特公司 用于眼治疗的制剂
US8222271B2 (en) 2006-03-23 2012-07-17 Santen Pharmaceutical Co., Ltd. Formulations and methods for vascular permeability-related diseases or conditions
ES2507078T3 (es) * 2007-08-16 2014-10-14 Santen Pharmaceutical Co., Ltd Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad

Also Published As

Publication number Publication date
SG11201802091RA (en) 2018-04-27
KR20180053340A (ko) 2018-05-21
MY183906A (en) 2021-03-17
TWI721015B (zh) 2021-03-11
WO2017047597A1 (ja) 2017-03-23
US10166217B2 (en) 2019-01-01
US20180271841A1 (en) 2018-09-27
PH12018500579A1 (en) 2018-09-10
MX393608B (es) 2025-03-24
JP6639364B2 (ja) 2020-02-05
EP3351244A4 (en) 2019-05-01
TW201717943A (zh) 2017-06-01
CN108025000A (zh) 2018-05-11
MX2018003381A (es) 2018-08-15
HK1256969A1 (en) 2019-10-04
HK1253545A1 (zh) 2019-06-21
EP3351244A1 (en) 2018-07-25
JP2017057199A (ja) 2017-03-23

Similar Documents

Publication Publication Date Title
EP3601536A4 (en) TREATMENT PROCESSES
EP3691549C0 (en) BLOOD OCCLUSION OR RESTRICTION SLEEVE
PT3528717T (pt) Dispositivos para tratamento de oclusão vascular
EP3335740C0 (en) Medical hydrogel
DK3347030T3 (da) Brug af pasteuriseret akkermansia til behandling af stofskiftesygdomme
PL3265053T3 (pl) Sposoby leczenia skóry
PL3936130T3 (pl) Schemat dawkowania walbenazyny w leczeniu hiperkinetycznych zaburzeń ruchu
DK3474804T3 (da) Medicinsk forbinding
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
PL3672954T3 (pl) Związki, ich sole i ich zastosowanie w leczeniu chorób
IL243485A0 (en) Methods for treating or preventing ophthalmological conditions
DK3474802T3 (da) Medicinsk forbinding
HUE055263T2 (hu) 11-Szubsztituált 24-hidroxiszterolok NMDA-hoz kapcsolódó állapotok kezelésére
EP3448263A4 (en) Electrotherapeutic treatment
IL254142B (en) Tredifitant for use in the treatment of a disease or medical condition that responds to Tredifitent
EP3723692A4 (en) MEDICAL ASSISTANT
PL3600374T3 (pl) Leczenie zakażenia układu oddechowego
EP3424557A4 (en) INTRAKARDIAL DEFIBRILLATION CATHETER
IL269083A (en) Methods for preventing and treating heart disease
EP3710095C0 (en) FRICTIONLESS CATHETER
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
IL253854B (en) Mebendazole polymorph for treatment and prevention of tumors
EP3597225A4 (en) TREATMENT PROCESS
EP3398537A4 (en) CAP FOR LEFT HEART OF EAR
DK3474803T3 (da) Medicinsk forbinding

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]